心房颤动合并既往颅内出血:抗凝治疗如何权衡获益与风险?

Balancing Risks and Benefits: Anticoagulation Strategies in Atrial Fibrillation Patients With Prior Intracranial Bleeding

This nationwide Finnish cohort study evaluates the competing risks of stroke, recurrent intracranial bleeding, and mortality with anticoagulation strategies in atrial fibrillation patients who had prior intracranial bleeding. It highlights the safer profile of DOACs versus warfarin in this high-risk population.
Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: Evidence and Insights from the NOTION-4 Trial

Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: Evidence and Insights from the NOTION-4 Trial

The NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding risk in anticoagulation strategies.
Timing of Atrial Fibrillation Diagnosis Does Not Alter Early Anticoagulation Benefits in Stroke Patients: Insights from the OPTIMAS Trial

Timing of Atrial Fibrillation Diagnosis Does Not Alter Early Anticoagulation Benefits in Stroke Patients: Insights from the OPTIMAS Trial

Subgroup analysis of the OPTIMAS trial reveals that neither the timing of atrial fibrillation diagnosis nor AF subtype modifies the treatment effect of early versus delayed direct oral anticoagulant initiation in acute ischemic stroke. Persistent AF, however, confers approximately double the risk of adverse outcomes compared with paroxysmal AF.
Pharmacist-Led Patient Self-Testing Superior to Usual Care for Warfarin Management in Mechanical Heart Valve Patients: Evidence from a Multicentre RCT in China

Pharmacist-Led Patient Self-Testing Superior to Usual Care for Warfarin Management in Mechanical Heart Valve Patients: Evidence from a Multicentre RCT in China

A multicentre RCT in China found that pharmacist-led patient self-testing (PST) significantly improves time in therapeutic range and reduces major bleeding and thromboembolism in patients with mechanical heart valves compared to traditional outpatient clinic care.
Factor XI Inhibition Redefined: Catalytic Domain Blockade Emerges as a Superior Strategy for VTE Prevention

Factor XI Inhibition Redefined: Catalytic Domain Blockade Emerges as a Superior Strategy for VTE Prevention

The ROXI-VTE trials demonstrate that inhibiting the Factor XI catalytic domain significantly reduces postoperative VTE compared to enoxaparin. While blocking Factor XIIa-mediated activation showed promise, it failed to meet superiority, highlighting the critical role of Factor XI's catalytic activity in surgical thromboprophylaxis.
Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management

Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management

A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, suggesting a need for more nuanced, individualized clinical decision-making.